Details for New Drug Application (NDA): 050614
✉ Email this page to a colleague
NDA 050614 describes KEFTAB, which is a drug marketed by Lilly and is included in one NDA. Additional details are available on the KEFTAB profile page.
The generic ingredient in KEFTAB is cephalexin hydrochloride. There are twenty-nine drug master file entries for this compound. Additional details are available on the cephalexin hydrochloride profile page.
The generic ingredient in KEFTAB is cephalexin hydrochloride. There are twenty-nine drug master file entries for this compound. Additional details are available on the cephalexin hydrochloride profile page.
Summary for 050614
| Tradename: | KEFTAB |
| Applicant: | Lilly |
| Ingredient: | cephalexin hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 250MG BASE | ||||
| Approval Date: | Oct 29, 1987 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 500MG BASE | ||||
| Approval Date: | Oct 29, 1987 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 333MG BASE | ||||
| Approval Date: | May 16, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
